AstraZeneca has announced favorable results from the BATURA Phase IIIb trial, revealing that AIRSUPRA effectively achieved the primary endpoint. The study demonstrated a statistically significant and clinically meaningful reduction in the risk of severe exacerbation compared to when using albuterol as an as-needed rescue medication. This trial involved participants with either intermittent or mild persistent asthma. The safety profile and tolerability of AIRSUPRA in the BATURA trial aligned with its known characteristics.
Sharon Barr, Executive Vice-President of BioPharmaceuticals R&D at AstraZeneca, remarked: "The remarkable results from the BATURA trial contribute further to the growing evidence that supports AIRSUPRA as a pioneering rescue treatment. It plays a significant role in decreasing the likelihood of asthma exacerbations across varying levels of disease severity and helps reduce reliance on systemic corticosteroids."
